Pacemakers Market Top Players and Growth Strategies

According to research report the pacemakers market is projected to reach USD 4.9 billion by 2023 from USD 4.4 billion in 2018, at a CAGR of 2.0% during the forecast period. The major driving factors in the pacemakers market are increasing prevalence of cardiovascular diseases and technological advancements in devices.
Read More: https://www.marketsandmarkets.com/ResearchInsight/pacemaker-market.asp
The major pacemaker’s vendors include Medtronic (Ireland), Abbott (US), and Boston Scientific (US) BIOTRONIK (Germany), LivaNova (UK), OSCOR (US), Pacetronix (India), MEDICO (Italy), Osypka Medical (Germany), and Lepu Medical (China). These players have adopted various growth strategies such as expansions, acquisitions, and new product launches to expand their presence in the global pacemakers market. Product launches has been the most dominating strategy adopted by major players from 2015 to 2018. This has helped them to expand their consumer base and address the unmet needs of end users.
In line with rising adoption of pacemaker devices, Medtronic focus on to develop innovative products for the treatment of heart rhythm disorders and heart failures. The company offers an extensive product portfolio for this market through its Cardiac and Vascular Group segment. It has a significant presence in more than 155 countries including major markets such as the US and Ireland. Medtronic focuses on organic growth strategies such as product launches to remain competitive in the market. In the last three years, it launched several products such as the Advisa and Ensura SR MRI SureScan Single-chamber Pacemaker Devices, Viva CRT-P Pacemaker, and Advisa DR MRI SureScan Pacing System.
Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=243344814
In 2017, Abbott acquired of St Jude Medical, this acquisition strengthened Abbott’s product offerings in the cardiovascular devices segment including pacemakers. The company offers a wide range of pacemaker products for cardiac rhythm management applications. Abbott is focusing on inorganic and organic growth strategies such as acquisitions and product launches. For example, in 2018, the company launched its smallest pacemaker, Assurity MRI and also receive CE mark approval for Nanostim leadless pacemaker in 2016. The company has a vast geographic presence and operated in 150 countries across the world. Abbott’s strong portfolio provides it with a competitive advantage in the market.